Sarepta Therapeutics
SRPT
323 hedge funds and large institutions have $1.93B invested in Sarepta Therapeutics in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 98 increasing their positions, 118 reducing their positions, and 65 closing their positions.
3.83% more ownership
Funds ownership: 98.04% → 101.87% (+3.8%)
6% less funds holding
Funds holding: 344 → 323 (-21)
14% less capital invested
Capital invested by funds: $2.23B → $1.93B (-$302M)
17% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 118
17% less call options, than puts
Call options by funds: $53.4M | Put options by funds: $64.6M
25% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 65
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$80.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$43.6M |
| 3 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$32.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$28M |
| 5 |
Goldman Sachs
New York
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$84.9M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$39.9M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$22.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11.5M |
SRPT Hedge Fund Activity: Q2 2026 in Review
323 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2026, worth a combined $1.93B — down 14% from $2.23B a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of SRPT and 49 opened new positions — a net loss of 16 holders — while 118 trimmed existing stakes and 98 added.
The largest buyer was BlackRock, adding an estimated $80.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $84.9M sold.
- 323 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2026, down from 344 in Q1 2026.
- Funds reported $1.93B of Sarepta Therapeutics stock for Q2 2026, down 14% quarter-over-quarter.
- 49 funds opened new Sarepta Therapeutics positions in Q2 2026 and 65 closed out, a net change of -16 holders.
- The largest Sarepta Therapeutics buyer in Q2 2026 was BlackRock, an estimated $80.2M added.
- The largest Sarepta Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $84.9M sold.
Based on aggregated 13F filings for Q2 2026.